Drug1st line2 diseases
Anakinra
IL-1 receptor antagonist
- Response rate
- ~94%
- Onset
- Hours–days
- Route
- SC 100mg daily
- Line
- 1st
- IgM effect
- No effect
- Evidence level
- green
Used across diseases
| Disease | Response rate | Line | Evidence |
|---|---|---|---|
| Schnitzler Syndrome | ~94% | 1st | green |
| Cryopyrin-Associated Periodic Syndromes | Sustained efficacy up to 5 years | 1st | green |
Evidence summary
Blocks IL-1 receptor. Cornerstone treatment — fever and rash resolve within hours, CRP normalises within days. ~94% response across all published cases.
Molecular targets
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| IL-1β | Central pathogenic driver | Elevated | established |